J. Jefferson Smith Sells 4,925 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 4,925 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $18,912.00. Following the completion of the transaction, the insider directly owned 121,926 shares of the company’s stock, valued at approximately $468,195.84. This represents a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

J. Jefferson Smith also recently made the following trade(s):

• On Wednesday, January 21st, J. Jefferson Smith sold 10,200 shares of Precision BioSciences stock. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $3.79 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. The stock’s fifty day moving average price is $4.11 and its 200 day moving average price is $5.00. Precision BioSciences, Inc. has a 1 year low of $3.53 and a 1 year high of $8.82. The company has a market cap of $86.79 million, a price-to-earnings ratio of -0.45 and a beta of 1.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $60.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. HBK Sorce Advisory LLC purchased a new stake in Precision BioSciences in the fourth quarter valued at $38,000. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences in the 4th quarter valued at about $43,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Precision BioSciences in the fourth quarter worth about $52,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Precision BioSciences in the third quarter worth about $72,000. Finally, Miller Financial Services LLC grew its holdings in Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares during the period. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.